Controversies in the treatment of androgenetic alopecia: The history of finasteride

被引：23

作者：

Andy, Goren ^{[1
]}

John, McCoy ^{[1
]}

Mirna, Situm ^{[2
]}

Rachita, Dhurat ^{[3
]}

Michael, Krychman ^{[1
]}

Maja, Kovacevic ^{[2
]}

Aseem, Sharma ^{[3
]}

Zeljana, Bolanca ^{[2
]}

机构：

[1] Appl Biol Inc, Irvine, CA USA

[2] Univ Hosp Ctr Sestre Milosrdnice, Dept Dermatol & Venereol, Vinogradska Cesta 29, Zagreb, Croatia

[3] LTM Med Coll & Hosp Sion, Dept Dermatol, Mumbai, Maharashtra, India

来源：

DERMATOLOGIC THERAPY | 2019年 / 32卷 / 02期

关键词：

androgenetic alopecia; finasteride; sexual dysfunction; DYSFUNCTION;

D O I：

10.1111/dth.12647

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Male androgenetic alopecia (AGA) affects up to 60% of men by the age of 50. Currently, there are only two approved drugs for the treatment of male AGA: topical minoxidil and oral finasteride. Topical minoxidil is readily available over the counter and has a well-established safety record. However, following 24 weeks of treatment, less than 40% of men respond to the drug. Additionally, due to the topical route of administration, compliance with minoxidil remains low. In contrast, oral finasteride, a 5-alpha reductase inhibitor, demonstrated efficacy in arresting hair loss in more than 80% of patients following 12 months of treatment. However, controversy surrounding potential adverse sexual side effects has negatively affected public perception of the drug and may significantly reduce the number of patients that can benefit from the drug.

引用

页数：3

共 11 条

[1] EMAS position statement: Testosterone replacement therapy in the aging male [J].